Progress against cancer (1971-2011): How far have we come?

Journal of Internal Medicine

Volumn 271, Issue 4, 2012, Pages 392-399

  Tiwari, A K ^a   Roy, H K ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Cancer; Cancer diagnosis; Cancer prevention; Cancer treatment; History of cancer; National cancer act

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; BEVACIZUMAB; CELECOXIB; CETUXIMAB; DASATINIB; EFLORNITHINE; ERLOTINIB; IMATINIB; MYC PROTEIN; NILOTINIB; PROTEIN KINASE B; PROTEIN P53; RETINOBLASTOMA PROTEIN; SELENIUM; SULINDAC; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; VEMURAFENIB; WART VIRUS VACCINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SCREENING; CHRONIC MYELOID LEUKEMIA; COLON ADENOMA; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIET SUPPLEMENTATION; FOOD AND DRUG ADMINISTRATION; GENE SEQUENCE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; MALIGNANT TRANSFORMATION; MEDICAL SOCIETY; MEDLINE; MELANOMA; METASTASIS; NOTE; ONCOGENE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SKIN CANCER; SMOKING CESSATION; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER;

HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEGISLATION AS TOPIC; MEDICAL ONCOLOGY; NEOPLASMS; UNITED STATES;

EID: 84858862564     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02462.x     Document Type: Note

References (50)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
3. The national cancer act of 1971. J Natl Cancer Inst 1972; 48: 577-84. PMID: 5058965.
4. Weinhouse S. National Cancer Act of 1971 - an editorial. Cancer Res 1972; 32: i-ii.
5. Bailar JC 3rd, Smith EM. Progress against cancer? N Engl J Med 1986; 314: 1226-32.
6. Bailar JC 3rd, Gornik HL. Cancer undefeated. N Engl J Med 1997; 336: 1569-74.
7. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
8. Kohler BA, Ward E, McCarthy BJ et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103: 714-36.
9. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
10. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-907.
11. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
12. Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976; 260: 170-3.
13. Bishop JM. Viral oncogenes. Cell 1985; 42: 23-38.
14. Klein G. The approaching era of the tumor suppressor genes. Science 1987; 238: 1539-45.
15. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
17. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
18. Botstein D. Genome-sequencing anniversary. Fruits of genome sequences for biology. Science 2011; 331: 1025.
19. Collins FS, Barker AD. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 2007; 296: 50-7.
20. White CS. National lung screening trial: a breakthrough in lung cancer screening? J Thorac Imaging 2011; 26: 86-7.
21. Thompson PA, Gerner EW. Current concepts in colorectal cancer prevention. Expert Rev Gastroenterol Hepatol 2009; 3: 369-82.
22. Smith L, Macneil S. State of the art in non-invasive imaging of cutaneous melanoma. Skin Res Technol 2011; Feb 22. doi: [Epub ahead of print].
23. Backman V, Roy HK. Light-scattering technologies for field carcinogenesis detection: a modality for endoscopic prescreening. Gastroenterology 2011; 140: 35-41.
24. Dunn BK, Wagner PD, Anderson D, Greenwald P. Molecular markers for early detection. Semin Oncol 2010; 37: 224-42.
25. Armakolas A, Panteleakou Z, Nezos A et al. Detection of the circulating tumor cells in cancer patients. Future Oncol 2010; 6: 1849-56.
26. Fisher B, Bauer M, Margolese R et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985; 312: 665-73.
27. Graziano C. HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP Today 1998; 12: 14-6.
28. Habeck M. FDA licences imatinib mesylate for CML. Lancet Oncol 2002; 3: 6.
29. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
30. Slevin M, Payne S. New treatments for colon cancer. BMJ 2004; 329: 124-6.
31. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
32. Brower V. Approval of provenge seen as first step for cancer treatment vaccines. J Natl Cancer Inst 2010; 102: 1108-10.
33. Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-9.
34. Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 2010; 16: 5972-80.
35. Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 2009; 69: 5269-84.
36. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. Br Med J 1950; 2: 739-48.
37. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36(7 Pt 2): 2699-702.
38. Rautalahti M, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Heinonen OP. Beta-carotene did not work: aftermath of the ATBC study. Cancer Lett 1997; 114: 235-6.
39. Lippman SM, Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
40. Ambrosone CB, Tang L. Cruciferous vegetable intake and cancer prevention: role of nutrigenetics. Cancer Prev Res (Phila) 2009; 2: 298-300.
41. Smigel K. Breast Cancer Prevention Trial shows major benefit, some risk. J Natl Cancer Inst 1998; 90: 647-8.
42. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finesteride on the development of prostate cancer. NEJM 2003; 349: 215-24.
43. Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-95.
44. Bertagnolli MM, Eagle CJ, Zauber AG et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-84.
45. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
46. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
47. Zhang L, Ren X, Alt E et al. Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 2010; 464: 1058-61.
48. Meyskens FL Jr, McLaren CE, Pelot D et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008; 1: 32-8.
49. Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) 2009; 2: 209-12.
50. DeWeerdt S. Food: the omnivore's labyrinth. Nature 2011; 471: S22-4.